🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Amneal Pharmaceuticals Inc Class A (AMRX)

NASDAQ
Currency in USD
8.730
+0.120(+1.39%)
Closed
After Hours
8.600-0.130(-1.489%)
AMRX Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
Day's Range
7.5208.755
52 wk Range
4.1508.950
Prev. Close
8.61
Open
8.15
Day's Range
7.52-8.755
52 wk Range
4.15-8.95
Volume
1,720,455
Average Volume (3m)
1,206,661
1-Year Change
110.36%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
AMRX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
10.500
Upside
+20.275%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings downwards for the upcoming period
Show more

Amneal Pharmaceuticals Inc Class A Company Profile

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson’s disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson’s disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Employees
7600

InvestingPro Research for Amneal Pharmaceuticals Inc Class A


Soaring Performance
Amneal Pharmaceuticals exceeds expectations across all segments, leading to a significant upward revision of revenue guidance and analyst optimism
Product Pipeline
Explore Amneal's expanding portfolio, including the launch of CREXONT and upcoming IPX203, driving revenue growth and market interest
Strategic Expansion
Delve into Amneal's foray into injectables and biosimilars, positioning the company for long-term growth in high-potential pharmaceutical segments
Market Outlook
Analysts set price targets ranging from $8 to $10, reflecting confidence in Amneal's growth trajectory amid competitive challenges and regulatory landscapes
Read full SWOT analysis

Compare AMRX to Peers and Sector

Metrics to compare
AMRX
Peers
Sector
Relationship
P/E Ratio
−14.7x−3.6x−0.6x
PEG Ratio
0.000.030.00
Price/Book
−28.9x1.2x2.6x
Price / LTM Sales
1.0x1.2x3.2x
Upside (Analyst Target)
8.8%1.7%44.1%
Fair Value Upside
Unlock9.4%6.2%Unlock

People Also Watch

183.07
IDCC
+2.13%
90.95
CALM
+1.77%
59.60
CORT
+9.76%
167.03
MHO
+1.64%
117.43
HIG
+1.94%

FAQ

What Is the Amneal Pharma A (AMRX) Stock Price Today?

The Amneal Pharma A stock price today is 8.73

What Stock Exchange Does Amneal Pharma A Trade On?

Amneal Pharma A is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Amneal Pharma A?

The stock symbol for Amneal Pharma A is "AMRX."

What Is the Amneal Pharma A Market Cap?

As of today, Amneal Pharma A market cap is 2.70B.

What is Amneal Pharma A Earnings Per Share?

The Amneal Pharma A EPS is -0.63.

What Is the Next Amneal Pharma A Earnings Date?

Amneal Pharma A will release its next earnings report on Feb 27, 2025.

From a Technical Analysis Perspective, Is AMRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.